ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2019

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.

J Veeraraghavan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.